Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2005-05-24
2005-05-24
Webman, Edward J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S464000, C424S449000, C424S422000, C424S423000
Reexamination Certificate
active
06896900
ABSTRACT:
Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a β-L-(2′ or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formulawherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′ is H, acyl, or alkyl.
REFERENCES:
patent: 4681933 (1987-07-01), Chu et al.
patent: 4841039 (1989-06-01), Chu et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 5075445 (1991-12-01), Jarvest et al.
patent: 5077279 (1991-12-01), Chu et al.
patent: 5084445 (1992-01-01), Chu et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5190926 (1993-03-01), Chu et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5641763 (1997-06-01), Holy et al.
patent: 5684010 (1997-11-01), Schinazi
patent: 5684153 (1997-11-01), Green et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5914331 (1999-06-01), Liotta et al.
patent: 4224737 (1994-02-01), None
patent: 0 409 227 (1991-01-01), None
patent: 0 494 119 (1992-07-01), None
patent: WO 9218517 (1992-10-01), None
patent: WO 9507086 (1995-03-01), None
patent: WO 9507287 (1995-03-01), None
patent: WO 9532984 (1995-12-01), None
patent: WO 96135512 (1996-05-01), None
patent: WO 9640164 (1996-12-01), None
patent: WO 9709052 (1997-03-01), None
patent: WO 9816186 (1998-04-01), None
Cheng et al.,Journal of Biological Chemistry, 1992, 267 (20), 13938-13942.
Furman et al., “The Anti-Hepatitis B Virus Activites, Cytoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-Hydroxymethyl)-1,3-oxathiolane-5-yl] Cytosine”Antimicrobial Agents and Chemotherapy, Dec. 1992, 2686-2692.
Gosselin et al., “Anti-HIV Activities of the β-L-Enantiomer of 2',3'-Dideoxycytidine and its 5-Fluoro Derivative in Vitro”Antimicrobial Agents and Chemotherapy, Jun. 1994, 38 (6), 1292-1297.
Lin et al.,J. Med. Chem., 1988, 31 (2), 336-340.
Mahmoudian,Pharm. Research, 1991, 8 (1), 43-46.
Nassal et al.,Trends in Microbiology, 1993, 1 (6), 221-228.
Tsai et al.,Biochem. Pharmacol., 1994, 48 (7), 1477-1481.
Gosselin Gilles
Imbach Jean-Louis
Schinazi Raymond F.
Sommadossi Jean-Pierre
Centre National de la Recherche Scientifique
Emory University
King & Spalding LLP
Knowles, Esq. Sherry M.
The UAB Research Foundation
LandOfFree
β-L-2'-deoxy-nucleosides for the treatment of HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β-L-2'-deoxy-nucleosides for the treatment of HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-L-2'-deoxy-nucleosides for the treatment of HIV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426752